1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy

Background

The immune checkpoint inhibitors (ICIs) revolutionized cancer therapeutic landscape and substantially improved the survival of patients (pts) with advanced malignancies. Several predictive biomarkers are under evaluation, in order to identify patients who can benefit from ICI. Recently, elevated NLR, calculated from absolute neutrophil count and white cell count, were found to be independent predictors of reduced survival and increased risk of progression in melanoma patients receiving ICI. The purpose of this study is to retrospectively investigate relationship of NLR with inflammation-immune mediators.

Methods

Gene profiling analysis was performed from 78 basal PBMCs of metastatic melanoma pts treated in first line with anti-PD1 using NanoString IO360 panel. Patient’s characteristics are listed in table. To identify the best genes signature the Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) was applied.

Results

Overall, 78 patients were included in the analysis. Pts with high NLR at baseline (ratio >5.57) had a poorer PFS (HR=7.27, 95% CI = 3.5-14.8; p < 0.0001) and OS (HR=3.98; 95% CI = 2.0-7.9) than the pts with low NLR. Brain metastases were present in a higher proportion of pts with high NLR compared to those with low NLR (p=0.01). In the trascriptomic analysis, NLR was associated with SH2D1A, CD3, ZAP70, CD45RA genes, while a high NLR with CCNA1, LDHA, IL18R1, CD39, PTEN, MYD88 and MMP9 genes (ROC curve, AUC=0.97, p<0001). The signatures are also associated to response. In addition, CD39 expression is higher in NLR high and is associate with increase of N2 neutrophils. NLR increase on treatment is also associated to worse outcome and a specific genetic signature. Table: 1163P

Conclusions

NLR high is related with immunosuppressive, inflammatory and tumor related genes; in particular with N2 neutrophils associate to adenosine pathway activation. This could explain the prognostic role of NLR. Further investigations are needed to get additional information.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Paolo Antonio Ascierto.

Funding

Italian Ministry of Health (IT-MOH).

Disclosure

A. White, M. Bailey, S. Ong, S.E. Church, S. Warren, A. Cesano: Financial Interests, Personal, Stocks or ownership: NanoString. P.A. Ascierto: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health. All other authors have declared no conflicts of interest.